Hemangiosarcoma: Advancing canine cancer treatment with targeted therapies – FidoCure

Canine cancer diagnoses can be devastating and demoralizing. While research and studies for human cancer have brought us a long way when it comes to treatment and instilling hope for our loved ones, the same can’t necessarily be said for the world of pet medicine. Despite this, there are many passionate veterinarians and veterinary oncologists out there who are helping to move the needle on pet cancer research and treatment. Taking cues from the progress made on human cancer treatment, FidoCure uses genomic testing to identify potential targeted therapies for their specific cancer profile. It also helps veterinarians and veterinary oncologists deduce effective therapies for future canine cancer cases. FidoCure has already shown that a prognosis can be enhanced through targeted therapies. Take hemangiosarcoma for instance…

Leave a Reply Cancel reply

DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. Access to therapy is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.

© Copyright 2018-2023 OHC, All rights reserved